Andrea Lukes
No ORCID on file
· 3 papers in corpus
rct
2023
BACKGROUND AND OBJECTIVE: Relugolix is a gonadotropin-releasing hormone receptor antagonist. Relugolix 40-mg monotherapy is associated with vasomotor symptoms and long-term bone mineral density loss due to hypoestrogenism. This study assess…
nonrandomized-trial
2020
Objective: This article reports on 3-year clinical outcomes of the Sonography Guided Transcervical Ablation of Uterine Fibroids (SONATA) pivotal trial of transcervical fibroid ablation (TFA) in women with symptomatic uterine myomata. Materi…
other
2015
Carolina Women's Research and Wellness Center, Durham, North Carolina Financial Disclosure The author did not report any potential conflicts of interest. Dr. Lukes is a current PI on an AEGEA clinical trial for endometrial ablations, and ga…